Alkem Laboratories has introduced single-shot pre-filled syringes of semaglutide in India, expanding delivery options for obesity and Type 2 diabetes treatment amid growing competition in the metabolic care market.
Pfizer has launched its bispecific antibody therapy elranatamab in India, marking a significant step forward in the treatment landscape for patients with relapsed or refractory multiple myeloma. The launch reinforces the company’s commitm...
For many couples, the experience of a dream baby comes with lots of queries and concerns. It is common knowledge that fertility treatment is an established procedure that is the same for each individual.
SII to manufacture Oxford Ebola vaccine with $8.6M CEPI funding as global agencies race to contain Africa outbreak, boosting India’s role in vaccine production.
NPPA revises ceiling price of Pfizer’s benzathine benzylpenicillin injection to Rs 13.42 per vial after DoP review, correcting pricing inputs under DPCO guidelines in India.
The Delhi High Court allowing Intas to sell cancer drug Bevatas has emerged as a significant development in India’s pharmaceutical sector, after the court overturned an earlier order that had favoured Sun Pharma in a trademark dispute.
India–Oman CEPA to boost pharma exports with zero-duty access, faster approvals, and reduced compliance, unlocking growth opportunities in Oman’s pharma market.
Moderna and the Coalition for Epidemic Preparedness Innovations (CEPI) have joined forces to accelerate the development of a vaccine for the Bundibugyo strain of Ebola, marking a major step in global efforts to strengthen outbreak preparedness.
A late-stage clinical trial has shown that daraxonrasib, an experimental pancreatic cancer drug, significantly improved survival and disease control in patients with advanced cancer after chemotherapy failure.
Understanding prostate cancer in India, including rising cases, symptoms, risk factors, treatment options, cost, and how innovation and healthcare advancements are shaping outcomes.